Products

AlloSource launched ProChondrix® Cartilage Restoration Matrix, a cellular 3D fresh allograft to support cartilage regeneration.

Fidia will commence U.S. launch of Hymovis® 2-injection highly viscoelastic hyaluronan, indicated to treat knee OA pain.

Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee OA.

Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. 

AlloSource was awarded U.S. Patent No. 9,186,253, Cartilage mosaic compositions and methods, for its ProChondrix® Cartilage Restoration Matrix allograft product.

BONESUPPORT announced the milestone of >20,000 patients treated worldwide to date with CERAMENT™ injectable drug-eluting bone substitute products.

Bioventus launched DUROLANE® single-injection hyaluronic acid-based osteoarthritis treatment in Taiwan.